Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.
about
An update on cladribine for relapsing-remitting multiple sclerosis.Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls.Immunophenotypic characterization of CSF B cells in virus-associated neuroinflammatory diseases.Role of CXCL13 in the formation of the meningeal tertiary lymphoid organ in multiple sclerosisSuccessful therapy with rituximab in three patients with probable neurosarcoidosis
P2860
Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Targeting B cells in relapsing ...... o optimal clinical management.
@en
type
label
Targeting B cells in relapsing ...... o optimal clinical management.
@en
prefLabel
Targeting B cells in relapsing ...... o optimal clinical management.
@en
P2093
P2860
P356
P1476
Targeting B cells in relapsing ...... to optimal clinical management
@en
P2093
Oliver M Grauer
Sven G Meuth
Tobias Ruck
P2860
P356
10.1177/1756285616666741
P577
2016-09-02T00:00:00Z